Persistent Fever as a Key Mortality Predictor in MRSA Bacteremia
Sean Ong Image credits: LinkedIn A post hoc analysis of the CAMERA2 randomized clinical trial has identified persistent fever after 72 hours as a key predictor of increased mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. In contrast, white blood cell (WBC) count and C-reactive protein (CRP) levels did not show the same predictive […]
Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) is a severe lung condition that causes fluid to build up in the lungs leading to difficulty breathing, shortness of breath, confusion, and dizziness and decompensate into complications such as blood clots and infections.1,2 About 25% to 40% of people with ARDS do not survive, even with treatment, which […]
Addressing the Threat of Candida Infections: Resistance and Management
Oliver Cornely Image credits: CECAD Cologne Candida species are the leading cause of fungal infections in hospitalized patients, contributing significantly to morbidity and mortality. Invasive candidiasis, including candidemia, primarily affects immunocompromised or critically ill individuals, while mucocutaneous candidiasis, such as oral thrush and vulvovaginal candidiasis, can occur in otherwise healthy individuals. While mucocutaneous forms are […]
New therapy may effectively control HIV in Uganda
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda. The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV […]
Recce Pharmaceuticals Reports Positive Data from Phase 2 Study for Gel for ABSSSI
Image credit: Recce Pharmaceuticals Sydney, Australia-based Recce Pharmaceuticals reported positive findings from its phase 2 study examining the efficacy and safety of its topical gel, R327G (RECCE 327), in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections (DFI). R327G demonstrated a 93% primary efficacy endpoint over 14 […]
Early Detection of Measles in Wastewater Highlights Silent Transmission Risks
Elke Wollants Image credits: LinkedIn Researchers have identified measles virus genotype D8 in wastewater samples from Brussels, Belgium, raising concerns about silent transmission in the region. The findings highlight the growing role of wastewater surveillance in tracking viral circulation and informing public health interventions. The study analyzed wastewater from Belgian treatment plants and detected measles […]
Investigational Staphylococcus aureus Vaccine Begins Trial
Produced by the National Institute of Allergy and Infectious Diseases (NIAID), this digitally colorized, scanning electron microscopic (SEM) image, depicts a clump of yellow-colored, spheroid shaped, Staphylococcus aureus bacteria that were enmeshed in a blue-colored, filamentous extracellular matrix, which normally binds cells together within the body’s various tissue types. Image credit: National Institute of Allergy […]
Measles Outbreak in Texas Expands to 58 Cases, Hospitalizations Increase
Measles rash Image credits: Unsplash The Texas Department of State Health Services (DSHS) has an updated report of the ongoing measles outbreak in the South Plains region of Texas. As of February 18, 2025, 58 cases have been identified, with symptoms starting within the past three weeks. 13 patients have been hospitalized, and four of […]
Designing antivirals for shape-shifting viruses
Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication. However, viruses are dynamic — constantly evolving and changing shape, which can make designing antiviral treatments a challenge. But new research utilizes an innovative computational modeling approach to […]
FDA Sets PDUFA Date for Lenacapavir For HIV Prevention
This morning, Gilead announced the FDA has accepted its new drug application (NDA) submissions for lenacapavir for the prevention of HIV as PrEP.1 The FDA will review the applications under priority review and has assigned a PDUFA target action date of June 19, 2025. If lenacapavir does get approved, it will be the first and […]
